Market capitalization | $12.97m |
Enterprise Value | $-34.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.56 |
P/B ratio (TTM) P/B ratio | 0.34 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-70.06m |
Free Cash Flow (TTM) Free Cash Flow | $-60.30m |
Cash position | $47.25m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
2 Analysts have issued a Leap Therapeutics, Inc. forecast:
2 Analysts have issued a Leap Therapeutics, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
98%
98%
|
|
EBITDA | -70 -70 |
19%
19%
|
EBIT (Operating Income) EBIT | -70 -70 |
20%
20%
|
Net Profit | -68 -68 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Doug Onsi |
Employees | 52 |
Founded | 2011 |
Website | www.leaptx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.